Page last updated: 2024-10-30

metformin and Blood Clot

metformin has been researched along with Blood Clot in 17 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)."9.34Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020)
"We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes."9.16Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012)
" In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome."8.82Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003)
" Metformin has a certain effect on anti-thrombosis, but its role and mechanism in MM-induced thrombosis are still uncovered."8.12Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532. ( Dai, X; De, Z; Gao, L; Hu, J; Li, G; Li, L; Xu, F; Zhang, Y, 2022)
"Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis."7.80Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. ( Chen, F; Lipinski, MJ; Pendyala, LK; Torguson, R; Waksman, R, 2014)
"Metformin, a first-line therapy for type 2 diabetes, is the only drug demonstrated to reduce cardiovascular complications in diabetic patients."5.43Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. ( Cao, Y; Gu, J; Huang, W; Ji, C; Lee, KH; Li, K; Lu, Y; Ma, L; Morris-Natschke, SL; Niu, H; Qin, C; Wei, Z; Wen, L; Xia, Q; Xin, G; Xing, Z; Yeh, JL; Zhang, R; Zheng, H, 2016)
" This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)."5.34Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020)
"We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes."5.16Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease. ( Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A, 2012)
" Metformin is a biguanide compound which is antihyperglycaemic, reduces insulin resistance and has cardioprotective effects on lipids, thrombosis and blood flow."4.82Beneficial effects of metformin on haemostasis and vascular function in man. ( Grant, PJ, 2003)
" In this context, metformin has been shown to not only contribute to a better glycaemic control but also to induce some weight loss (especially in the visceral depot) which may contribute to the improvement of the features of the metabolic syndrome."4.82Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes. ( Després, JP, 2003)
" Metformin has a certain effect on anti-thrombosis, but its role and mechanism in MM-induced thrombosis are still uncovered."4.12Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532. ( Dai, X; De, Z; Gao, L; Hu, J; Li, G; Li, L; Xu, F; Zhang, Y, 2022)
"Recent studies have suggested that metformin may inhibit endothelialization following limus-eluting stent (LES) placement and may increase the risk of stent thrombosis."3.80Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin. ( Chen, F; Lipinski, MJ; Pendyala, LK; Torguson, R; Waksman, R, 2014)
"Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a leading cause of mortality and disability worldwide."1.56Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke. ( Chen, Z; He, Y; Huang, W; Ji, C; Lee, KH; Li, S; Li, Y; Ming, Y; Morris-Natschke, SL; Niu, H; Wei, Z; Xin, G; Xing, Z; Yang, X; Yu, K; Zhang, B; Zhang, J; Zhang, X, 2020)
"Metformin, a first-line therapy for type 2 diabetes, is the only drug demonstrated to reduce cardiovascular complications in diabetic patients."1.43Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release. ( Cao, Y; Gu, J; Huang, W; Ji, C; Lee, KH; Li, K; Lu, Y; Ma, L; Morris-Natschke, SL; Niu, H; Qin, C; Wei, Z; Wen, L; Xia, Q; Xin, G; Xing, Z; Yeh, JL; Zhang, R; Zheng, H, 2016)
"Metformin pre-treatment also reduced endothelial cell damage in ferrous chloride induced thrombosis in carotid arteries."1.37Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats. ( Bhadada, SV; Dhamecha, PS; Ghatak, SB; Panchal, SJ, 2011)

Research

Studies (17)

TimeframeStudies, this research(%)All Research%
pre-19902 (11.76)18.7374
1990's0 (0.00)18.2507
2000's3 (17.65)29.6817
2010's6 (35.29)24.3611
2020's6 (35.29)2.80

Authors

AuthorsStudies
Xin, G2
Ming, Y1
Ji, C2
Wei, Z2
Li, S1
Morris-Natschke, SL2
Zhang, X2
Yu, K1
Li, Y1
Zhang, B1
Zhang, J1
Xing, Z2
He, Y1
Chen, Z1
Yang, X1
Niu, H2
Lee, KH2
Huang, W3
Usman, A1
Bliden, KP1
Cho, A1
Walia, N1
Jerjian, C1
Singh, A1
Kundan, P1
Duhan, S1
Tantry, US1
Gurbel, PA1
Gao, L1
Li, L1
Hu, J1
Li, G1
Zhang, Y1
Dai, X1
De, Z1
Xu, F1
Wang, Y1
Fu, M1
Xiao, W1
Zhao, Y1
Yuan, P1
Wu, W1
Menendez, JA1
Werida, R1
Kabel, M1
Omran, G1
Shokry, A1
Mostafa, T1
Soberanes, S1
Misharin, AV1
Jairaman, A1
Morales-Nebreda, L1
McQuattie-Pimentel, AC1
Cho, T1
Hamanaka, RB1
Meliton, AY1
Reyfman, PA1
Walter, JM1
Chen, CI1
Chi, M1
Chiu, S1
Gonzalez-Gonzalez, FJ1
Antalek, M1
Abdala-Valencia, H1
Chiarella, SE1
Sun, KA1
Woods, PS1
Ghio, AJ1
Jain, M1
Perlman, H1
Ridge, KM1
Morimoto, RI1
Sznajder, JI1
Balch, WE1
Bhorade, SM1
Bharat, A1
Prakriya, M1
Chandel, NS1
Mutlu, GM1
Budinger, GRS1
Habib, A1
Karmali, V1
Polavarapu, R1
Akahori, H1
Pachura, K1
Finn, AV1
Lipinski, MJ1
Pendyala, LK1
Torguson, R1
Chen, F1
Waksman, R1
Zheng, H1
Gu, J1
Ma, L1
Yeh, JL1
Zhang, R1
Qin, C1
Wen, L1
Cao, Y1
Xia, Q1
Lu, Y1
Li, K1
Ghatak, SB1
Dhamecha, PS1
Bhadada, SV1
Panchal, SJ1
Klempfner, R1
Leor, J1
Tenenbaum, A1
Fisman, EZ1
Goldenberg, I1
Stiefelhagen, P1
Grant, PJ1
Després, JP1
Gormsen, J1
Laursen, B1
Fearnley, GR1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560]Phase 480 participants (Actual)Interventional2018-10-08Completed
A Pilot Study: Metformin as an Inflammatory Modulating Therapy in Older Adults Without Diabetes[NCT03772964]Phase 1/Phase 232 participants (Actual)Interventional2019-01-22Completed
DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388]Phase 374 participants (Actual)Interventional2017-02-07Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes From Baseline in Grip Strength Via a Dynamometer During and Following Exposure to Metformin.

Grip strength over time. (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)

,,,
InterventionmmHg (Mean)
0 days90 days, compared to 0 days120 days, compared to 0 days
1000mg Exposure28.9-0.41.1
1500mg Exposure25.7-.2.3
500mg Exposure28.2-5.3.1
Placebo25.7-.3-.6

Changes From Baseline in Short Physical Performance Battery (SPPB) During and Following Exposure to Metformin.

The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The minimum is zero (worse performance) and the maximum is 12 (best performance). (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)

,,,
InterventionUnits on a scale (Mean)
0d90d, change from 0d120d, change from 0d
1000mg Exposure10.80.40.2
1500mg Exposure11.10.40.3
500mg Exposure11.2-0.30
Placebo10.61.00.5

Measure the Rate of Clotting of Peripheral Blood With Whole Blood Aggregometry in Response to Collagen.

Aggregometry area under the curve with the Y-axis being % aggregometry and the X-axis time in minutes. (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)

,,,
Interventionarbitrary units*mins (Mean)
0 days30 day change from day 060 days change from day 090 days change from day 0120 days change from day 0
1000mg Exposure678.9-23.52.41.0
1500mg Exposure196-166.7-139.8-222.5-196.7
500mg Exposure56.3-34.7-28.31.6-49.2
Placebo83.3-29.6-49.4-66.6-47.6

Quantify the Bacterial Population Profile of the Microbiome Via Stool Samples.

"Bacterial communities using 16S rRNA sequencing in relationship to metformin dosing over time. Species richness or diversity in the sample is measured by Choa1 metric. Chao1 is an estimate of how many species are present in an ecosystem. In general, having more species is considered to be healthier and these values typically range from 100-200 for fecal samples. The Chao1 index over numerous samples across time are explored to understand treatment effects." (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)

,,,
InterventionIndex (Mean)
Day 0Day 30Day 60Day 90Day 120
1000mg Exposure107.6130.7137.9135142.2
1500mg Exposure128.1128.1128.6138.2144.2
500mg Exposure136.5139.9121.4137.8134
Placebo141.5144.75134.3152159.2

Reviews

2 reviews available for metformin and Blood Clot

ArticleYear
Beneficial effects of metformin on haemostasis and vascular function in man.
    Diabetes & metabolism, 2003, Volume: 29, Issue:4 Pt 2

    Topics: Arteriosclerosis; Blood Coagulation; Blood Platelets; Blood Vessels; Cardiovascular Diseases; Diabet

2003
Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Diabetes & metabolism, 2003, Volume: 29, Issue:4 Pt 2

    Topics: Abdomen; Adipose Tissue; Arteriosclerosis; Blood Glucose; Body Constitution; Cardiovascular Diseases

2003

Trials

2 trials available for metformin and Blood Clot

ArticleYear
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
    Diabetes research and clinical practice, 2020, Volume: 170

    Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus,

2020
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
    Cardiovascular diabetology, 2012, Jun-06, Volume: 11

    Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2;

2012

Other Studies

13 other studies available for metformin and Blood Clot

ArticleYear
Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.
    European journal of medicinal chemistry, 2020, Aug-15, Volume: 200

    Topics: Administration, Oral; Animals; Biguanides; Brain Ischemia; Dose-Response Relationship, Drug; Male; M

2020
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.
    Journal of thrombosis and thrombolysis, 2022, Volume: 53, Issue:2

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus; Hospitalization; Humans; Hypoglycemic Agents;

2022
Metformin Inhibits Multiple Myeloma Serum-induced Endothelial Cell Thrombosis by Down-Regulating miR-532.
    Annals of vascular surgery, 2022, Volume: 85

    Topics: Cells, Cultured; Endothelial Protein C Receptor; Fibrinolytic Agents; Human Umbilical Vein Endotheli

2022
3D Elastomeric Stent Functionalized with Antioxidative and Perivascular Tissue Regenerative Activities Ameliorated PVT Deprivation-Induced Vein Graft Failure.
    Advanced healthcare materials, 2023, Volume: 12, Issue:29

    Topics: Animals; Antioxidants; Hyperplasia; Metformin; Reactive Oxygen Species; Stents; Thrombosis

2023
Metformin and SARS-CoV-2: mechanistic lessons on air pollution to weather the cytokine/thrombotic storm in COVID-19.
    Aging, 2020, 05-27, Volume: 12, Issue:10

    Topics: Aged; Betacoronavirus; Calcium Release Activated Calcium Channels; Coronavirus Infections; COVID-19;

2020
Metformin Targets Mitochondrial Electron Transport to Reduce Air-Pollution-Induced Thrombosis.
    Cell metabolism, 2019, 02-05, Volume: 29, Issue:2

    Topics: Air Pollution; Animals; Cell Line; Cytokines; Electron Transport; Humans; Interleukin-6; Lung Diseas

2019
Metformin impairs endothelialization after placement of newer generation drug eluting stents.
    Atherosclerosis, 2013, Volume: 229, Issue:2

    Topics: Angioplasty, Balloon; Animals; Disease Models, Animal; Drug-Eluting Stents; Endothelium, Vascular; E

2013
Stent thrombosis is not increased following percutaneous coronary intervention in patients with non-insulin dependent diabetes mellitus taking metformin.
    Atherosclerosis, 2014, Volume: 235, Issue:2

    Topics: Aged; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Female; Humans; Male; Metformin; Middle Aged;

2014
Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release.
    Scientific reports, 2016, 11-02, Volume: 6

    Topics: Animals; Blood Platelets; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Electron Transport Complex

2016
Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats.
    European journal of pharmacology, 2011, Jun-01, Volume: 659, Issue:2-3

    Topics: Animals; Antioxidants; Aorta; Atherosclerosis; Blood Coagulation; Body Weight; Carotid Arteries; Cho

2011
[Stroke is not equal to stroke. Keep track of the causes].
    MMW Fortschritte der Medizin, 2003, Volume: 145 Suppl 1

    Topics: Adult; Antihypertensive Agents; Aspirin; Carotid Artery, Common; Carotid Artery, External; Carotid S

2003
Studies on pharmacological enhancement of blood fibrinolytic activity.
    Angiology, 1970, Volume: 21, Issue:8

    Topics: Aged; Arteriosclerosis; Clofibrate; Female; Fibrinogen; Fibrinolysis; Fibrinolytic Agents; Humans; I

1970
[Physiological and pharmacological aspects of fibrinolysis].
    La Clinica terapeutica, 1971, May-15, Volume: 57, Issue:3

    Topics: Adrenal Cortex Hormones; Anabolic Agents; Arteriosclerosis Obliterans; Biguanides; Blood Coagulation

1971